Abstract
The thrombin-fibrinogen interaction to form the fibrin clot proceeds in three reversible steps (Scheraga and Laskowski, 1957), with thrombin being involved in only the first one:
-
Step 1
Proteolysis \({\text{F}}\,\overset {\text{T}} \leftrightarrows \,{\text{f + P}} \)
-
Step 2
Polymerization \(nf \rightleftarrows {f_n} \)
-
Step 3
Clotting \(m{{\text{f}}_n} \rightleftarrows {\text{fibrin}} \)
where F is fibrinogen, T is thrombin, f is the fibrin monomer, P represents the fibrinopeptides A and B (two each) released by proteolytic cleavage of the Arg—Gly bonds in the Aα and Bβ chains, respectively, of fibrinogen, fn is a series of intermediate, rodlike staggered overlapped polymers of variable length (i.e., varying n), and fibrin is the clotted product formed by the incorporation of m rodlike polymers in an organized networklike structure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bagdy, D., Barabas, E., Graf, L., Petersen, T. E., and Magnusson, S., 1976, Hirudin, Methods Enzymol. 45: 669–678.
Blombäck, B., Blombäck, M., Olsson, P., Svendsen, L., and Åberg, G., 1969, Synthetic peptides with anticoagulant and vasodilating activity, Scand. J. Clin. Lab. Invest. Suppl. 24 (107): 59–64.
Bothner-By, A. A., Stephens, R. L., Lee, J.-M., Warren, C. D., and Jeanloz, R. W., 1984, Structure determination of a tetrasaccharide: Transient nuclear Overhauser effects in the rotating-frame,. J. Am. Chem. Soc. 106: 811–813.
Braun, P. J., Dennis, S., Hofsteenge, J., and Stone, S. R., 1988, Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin, Biochemistry 27: 6517–6521.
Brown, L. R., and Farmer, B. T., II, 1989, Rotating-frame nuclear Overhauser effect, Methods Enzymol. 176: 199–217.
Chang, J.-Y., 1983, The functional domain of hirudin: A thrombin-specific inhibitor, FEBS Lett. 164: 307–313.
Dodt, J., Müller, H.-P., Seemüller, U., and Chang, J.-Y., 1984, The complete amino acid sequence of hirudin, a thrombin specific inhibitor: Application of colour carboxymethylation, FEBS Lett. 165: 180–183.
Dodt, J. Seemüller, U., and Fritz, H., 1987, Influence of chain shortening on the inhibitory properties of hirudin and eglin c, Biol. Chem. Hoppe-Seyler 368: 1447–1453.
Endres, G. F., Ehrenpreis, S., and Scheraga, H. A., 1966, Equilibria in the fibrinogen-fibrin conversion. VI. Ionization changes in the reversible polymerization of fibrin monomer, Biochemistry 5: 1561–1567.
Folkers, P. J. M., Clore, G. M., Driscoll, P. C., Dodt, J., Köhler, S., and Gronenborn, A. M., 1989, Solution structure of recombinant hirudin and the Lys-47 to Glu mutant: A nuclear magnetic resonance and hybrid distance geometry-dynamical simulated annealing study, Biochemistry 28: 2601–2617.
Gibson, K. D., and Scheraga, H. A., 1987, Revised algorithms for the build-up procedure for predicting protein conformations by energy minimization, J. Comput. Chem. 8: 826–834.
Hanna, L. S., Scheraga, H. A., Francis, C. W., and Marder, V. J., 1984, Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides, Biochemistry 23: 4681–4687.
Haruyama, H., and Wüthrich, K., 1989, Conformation of recombinant desulfatohirudin in aqueous solution determined by nuclear magnetic resonance, Biochemistry 28: 4301–4311.
Kettner, C., and Shaw, E., 1979, D-Phe-Pro-ArgCH2CI—a selective affinity label for thrombin, Thromb. Res. 14: 969–973.
Kikumoto, R., Tamao, Y., Tezuka, T., Tonomura, S., Hara, H., Ninomiya, K., Hijikata, A., and Okamoto, S., 1984, Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2[(3-methyl-1, 2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2-piperidinecarboxylic acid, Biochemistry 23: 85–90.
Krstenansky, J. L., and Mao, S.J. T., 1987, Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Na-acetyl-hirudin45_85, FEBS Lett. 211: 10–16.
Krstenansky, J. L., Broersma, R. J., Owen, T. J., Payne, M. H., Yates, M. T., and Mao, S. J. T., 1990, Development of MDL 28,050, a small stable antithrombin agent based on a functional domain of the leech protein, hirudin, Thromb. Haemostasis 63: 208–214.
Laskowski, M., Jr., Ehrenpreis, S., Donnelly, T. H., and Scheraga, H. A., 1960, Equilibria in the fibrinogen-fibrin conversion. V. Reversibility and thermodynamics of the proteolytic action of thrombin on fibrinogen, J. Am. Chem. Soc. 82: 1340–1348.
Laudano, A. P., and Doolittle, R. F., 1980, Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences, Biochemistry 19: 1013–1019.
Li, Z., and Scheraga, H. A., 1987, Monte Carlo-minimization approach to the multiple- minima problem in protein folding, Proc. Natl. Acad. Sci. USA 84: 6611–6615.
Mao, S. J. T., Yates, M. T., Owen, T. J., and Krstenansky, J. L., 1988, Interaction of hirudin with thrombin: Identification of a minimal binding domain of hirudin that inhibits clotting activity, Biochemistry 27: 8170–8173.
Maraganore, J. M., Chao, B., Joseph, M. L., Jablonski, J., and Ramachandran, K. L., 1989, Anticoagulant activity of synthetic hirudin peptides, J. Biol. Chem. 264: 8692–8698.
Markwardt, F., 1970, Hirudin as an inhibitor of thrombin, Methods Enzymol. 19: 924–932.
Marsh, H. C., Jr., Meinwald, Y. C., Lee, S., and Scheraga, H. A., 1982, Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of phenylalanine at position P9, Biochemistry 21: 6167–6171.
Marsh, H. C., Jr., Meinwald, Y. C., Thannhauser, T. W., and Scheraga, H. A., 1983, Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of aspartic acid at position P10, Biochemistry 22: 4170–4174.
Marsh, H. C., Jr., Meinwald, Y. C., Thannhauser, T. W., and Scheraga, H. A., 1983, Mechanism of action of thrombin on fibrinogen. Direct evidence for the involvement of aspartic acid at position P10, Biochemistry 22: 4170–4174.
Martinelli, R. A., and Scheraga, H. A., 1980, Steady-state kinetics study of the bovine thrombin-fibrinogen interaction, Biochemistry 19: 2343–2350.
Meinwald, Y. C., Martinelli, R. A., van Nispen, J. W., and Scheraga, H. A., 1980, Mechanism of action of thrombin on fibrinogen. Size of the Act fibrinogen-like peptide that contacts the active site of thrombin, Biochemistry 19: 3820–3825.
Momany, F. A., McGuire, R. F., Burgess, A. W., and Scheraga, H. A., 1975, Energy parameters in polypeptides. VII. Geometric parameters, partial atomic charges, nonbonded interactions, hydrogen bond interactions, and intrinsic torsional potentials for the naturally occurring amino acids, J. Phys. Chem. 79: 2361–2381.
Nagy, J. A., Meinwald, Y. C., and Scheraga, H. A., 1982, Immunochemical determination of conformational equilibria for fragments of the Aα chain of fibrinogen, Biochemistry 21: 1794–1806.
Nagy, J. A., Meinwald, Y. C., and Scheraga, H. A., 1985, Immunochemical determination of conformational equilibria for fragments of the Bß chain of fibrinogen, Biochemistry 24: 882–887.
Némethy, G., Pottle, M. S., and Scheraga, H. A., 1983, Energy parameters in polypeptides. 9. Updating of geometric parameters, nonbonded interactions, and hydrogen bond interactions for the naturally occurring amino acids, J. Phys. Chem. 87: 1883–1887.
Ni, F., Scheraga, H. A., and Lord, S. T., 1988, High-resolution NMR studies of fibrinogen-like peptides in solution: Resonance assignments and conformational analysis of residues 1–23 of the Au chain of human fibrinogen, Biochemistry 27: 4481–4491.
Ni, F., Konishi, Y., Bullock, I,. D., Rivetna, M. N., and Scheraga, H. A., 1989a, High-resolution NMR studies of fibrinogen-like peptides in solution: Structural basis for the bleeding disorder caused by a single mutation of Gly(12) to Val(12) in the Ao. chain of human fibrinogen Rouen, Biochemistry 28: 3106–3119.
Ni, F., Konishi, Y., Frazier, R. B., Scheraga, H. A., and Lord, S. T., 1989b, High-resolution NMR studies of fibrinogen-like peptides in solution: Interaction of thrombin with residues 1–23 of the Au chain of human fibrinogen, Biochemistry 28: 3082–3094.
Ni, F., Meinwald, Y. C., Vasquez, M., and Scheraga, H. A., 1989c, High-resolution NMR studies of fibrinogen-like peptides in solution: Structure of a thrombin-bound peptide corresponding to residues 7–16 of the Au chain of human fibrinogen, Biochemistry 28: 3094–3105.
Ni, F., Konishi, Y., and Scheraga, H. A., 1990, Thrombin-bound conformation of the C-terminal fragments of hirudin determined by transferred nuclear Overhauser effects, Biochemistry 29: 4479–4489.
Pincus, M. R., Klausner, R. D., and Scheraga, H. A., 1982, Calculation of the three-dimensional structure of the membrane-bound portion of melittin from its amino acid sequence, Proc. Natl. Acad. Sci. USA 79: 5107–5110.
Rae, I. D., and Scheraga, H. A., 1979, 1H and 13C nuclear magnetic resonance spectra of some peptides with fibrinogen-like activity, Int. J. Pept. Protein Res. 13: 304–314.
Scheraga, H. A., 1983, Interaction of thrombin and fibrinogen and the polymerization of fibrin monomer, Ann. N.Y. Acad. Sci. 408: 330–343.
Scheraga, H. A., 1986, Chemical basis of thrombin interactions with fibrinogen, Ann. N.Y. Acad. Sei. 485: 124–133.
Scheraga, H. A., and Laskowski, M., Jr., 1957, The fibrinogen-fibrin conversion, Adv. Protein Chem. 12: 1–131.
Sippl, M. J., Némethy, G., and Scheraga, H. A., 1984, Intermolecular potentials from crystal data. 6. Determination of empirical potentials for O—H • • • O=C hydrogen bonds from packing configurations, J. Phys. Chem. 88: 6231–6233.
Sonder, S. A., and Fenton, J. W., II, 1984, Proflavin binding within the fibrinopeptide groove adjacent to the catalytic site of human a-thrombin, Biochemistry 23: 1818–1823.
Southan, C., 1988, Molecular and genetic abnormalities of fibrinogen, in: Fibrinogen, Fibrin Stabilization, and Fibrinolysis: Clinical, Biochemical and Laboratory Aspects ( J. L. Francis, ed.), Ellis Horwood VCH, England, pp. 65–99.
Stone, S. R., and Hofsteenge, J., 1986, Kinetics of the inhibition of thrombin by hirudin, Biochemistry 25: 4622–4628.
Sturtevant, J. M., Laskowski, M., Jr., Donnelly, T. H., and Scheraga, H. A., 1955, Equilibria in the fibrinogen-fibrin conversion. III. Heats of polymerization and clotting of fibrin monomer, J. Am. Chem. Soc. 77: 6168–6172.
Stürzebecher, J., Markwardt, F., Voigt, B., Wagner, G., and Walsmann, P., 1983, Cyclic amides of N“-arylsulfonyl-aminoacylated 4-amidinophenylalanine—tight binding inhibitors of thrombin, Thromb. Res. 29: 635–642.
van Nispen, J. W., Hageman, T. C., and Scheraga, H. A., 1977, Mechanism of action of thrombin on fibrinogen: The reaction of thrombin with fibrinogen-like peptides containing 11, 14, 16 residues, Arch. Biochem. Biophys. 182: 227–243.
Varadi, A., and Scheraga, H. A., 1986, Localization of segments essential for polymerization and for calcium binding in the y-chain of human fibrinogen, Biochemistry 25: 519–528.
Wallace, A., Dennis, S., Hofsteenge, J., and Stone, S. R., 1989, Contribution of the N-terminal region of hirudin to its interaction with thrombin, Biochemistry 28: 10079–10084.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ni, F., Gibson, K.D., Scheraga, H.A. (1992). Nuclear Magnetic Resonance Studies of Thrombin-Fibrinopeptide and Thrombin-Hirudin Complexes. In: Berliner, L.J. (eds) Thrombin. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3296-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3296-5_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6450-4
Online ISBN: 978-1-4615-3296-5
eBook Packages: Springer Book Archive